Earnout Pan Out? Biomarin's Deals Progressing Years Later

The buyout of Talon Therapeutics Inc. by Spectrum Pharmaceuticals Inc. for $11.3 million in cash up front and contingent value rights (CVRs) for up to $195 million indicate that the earnout deal remains alive and well in biotech.